Current prognostic models for acute myeloid leukemia (AML) are inconsistent at predicting clinical outcomes for individual patients. Variability in the quality of specimens utilized for biomarker discovery and validation may contribute to this prognostic inconsistency.
Methods:
We evaluated the impact of sample heterogeneity on prognostic biomarkers and methods to mitigate any adverse effects of this heterogeneity in 240 cryopreserved bone marrow and peripheral blood specimens from AML patients enrolled on SWOG (Southwest Oncology Group) trials.
Results:
Cryopreserved samples displayed a broad range in viability (37% with viabilities ≤60%) and nonleukemic cell contamination (13% with lymphocyte percentages >20%). Specimen viability was impacted by transport time, AML immunophenotype, and, potentially, patients' age. The viability and cellular heterogeneity in unsorted samples significantly altered biomarker results. Enriching for viable AML blasts improved the RNA quality from specimens with poor viability and refined results for both DNA and RNA biomarkers. For example, FLT3-ITD allelic ratio, which is currently utilized to risk-stratify AML patients, was on average 1.49-fold higher in the viable AML blasts than in the unsorted specimens.
Conclusion:
To our knowledge, this is the first study to provide evidence that using cryopreserved specimens can introduce uncontrollable variables that may impact biomarker results and enrichment for viable AML blasts may mitigate this impact.
Get full access to this article
View all access options for this article.
References
1.
SteinEM, TallmanMS. Emerging therapeutic drugs for AML. Blood, 2016; 127:71–78.
MrozekK, MarcucciG, NicoletD, et al.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol, 2012; 30:4515–4523.
4.
CornelissenJJ, BlaiseD. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood, 2016; 127:62–70.
5.
MeshinchiS, WoodsWG, StirewaltDL, et al.Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 2001; 97:89–94.
6.
StirewaltDL, KopeckyKJ, MeshinchiS, et al.FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 2001; 97:3589–3595.
7.
PreudhommeC, SagotC, BoisselN, et al.Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood, 2002; 100:2717–2723.
8.
SchnittgerS, SchochC, DugasM, et al.Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 2002; 100:59–66.
9.
ThiedeC, KochS, CreutzigE, et al.Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 2006; 107:4011–4020.
10.
BullingerL, RuckerFG, KurzS, et al.Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood, 2007; 110:1291–1300.
11.
MarcucciG, MaharryK, WhitmanSP, et al.High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol, 2007; 25:3337–3343.
12.
GaleRE, GreenC, AllenC, et al.The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 2008; 111:2776–2784.
13.
LangerC, MarcucciG, HollandKB, et al.Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol, 2009; 27:3198–3204.
14.
DammF, OberackerT, TholF, et al.Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol, 2011; 29:682–689.
15.
StaffasA, KanduriM, HovlandR, et al.Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood, 2011; 118:5905–5913.
16.
PatelJP, GonenM, FigueroaME, et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 2012; 366:1079–1089.
17.
GaidzikVI, SchlenkRF, PaschkaP, et al.Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: Results of the AML Study Group (AMLSG). Blood, 2013; 121:4769–4777.
18.
DammF, MarkusB, TholF, et al.TET2 mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns. Genes Chromosomes Cancer, 2014; 53:824–832.
19.
OstronoffF, OthusM, LazenbyM, et al.Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol, 2015; 33:1157–1164.
20.
WilsonCS, DavidsonGS, MartinSB, et al.Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood, 2006; 108:685–696.
21.
RockovaV, AbbasS, WoutersBJ, et al.Risk stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and gene expression markers. Blood, 2011; 118:1069–1076.
22.
MarcucciG, YanP, MaharryK, et al.Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score. J Clin Oncol, 2014; 32:548–556.
23.
EngelKB, VaughtJ, MooreHM. National Cancer Institute Biospecimen Evidence-Based Practices: A novel approach to pre-analytical standardization. Biopreserv Biobank, 2014; 12:148–150.
24.
DeMartinoJK. NCCN Work Group Report: Emerging issues in tissue allocation. J Natl Compr Canc Netw, 2016; 14:265–271.
25.
Institute NC. Biorepositories and Biospecimen Research Branch. Vol. 2016. Rockville, MD: National Cancer Institute, NIH; 2016.
26.
LehmannS, GuadagniF, MooreH, et al.Standard preanalytical coding for biospecimens: Review and implementation of the Sample PREanalytical Code (SPREC). Biopreserv Biobank, 2012; 10:366–374.
27.
BetsouF, GunterE, ClementsJ, et al.Identification of evidence-based biospecimen quality-control tools: A report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. J Mol Diagn, 2013; 15:3–16.
28.
MatzkeEA, O'DonoghueS, BarnesRO, et al.Certification for biobanks: The program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank, 2012; 10:426–432.
29.
BarnesR, AlbertM, DamarajuS, et al.Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience. Biopreserv Biobank, 2013; 11:387–396.
30.
LangsethH, LuostarinenT, BrayF, DillnerJ. Ensuring quality in studies linking cancer registries and biobanks. Acta Oncol, 2010; 49:368–377.
31.
YongWH, DrySM, ShabihkhaniM. A practical approach to clinical and research biobanking. Methods Mol Biol, 2014; 1180:137–162.
32.
CaixeiroNJ, LaiK, LeeCS. Quality assessment and preservation of RNA from biobank tissue specimens: A systematic review. J Clin Pathol, 2016; 69:260–265.
33.
BetsouF, BullaA, ChoSY, et al.Assays for qualification and quality stratification of clinical biospecimens used in research: A technical report from the ISBER Biospecimen Science Working Group. Biopreserv Biobank, 2016; 14:398–409.
34.
MirandaLB, WyattK, JohnstonI, MilljanicM, ChaffeyJ. “Proof of concept” pilot study: Bioprocess chain of custody and bioresource sample management temperature observations. Sample level temperature trends and stability data obtained via utilization of bluechiip((R)) temperature tracking technology. Biopreserv Biobank, 2013; 11:115–121.
35.
SunJ, KilC, StankewichMC, YaoZ, LiJ, VortmeyerAO. A 10-minute prototype assay for tissue degradation monitoring in clinical specimens. Exp Mol Pathol, 2015; 99:86–94.
36.
KofanovaOA, MathiesonW, ThomasGA, BetsouF. DNA fingerprinting: A quality control case study for human biospecimen authentication. Biopreserv Biobank, 2014; 12:151–153.
37.
MooreHM, KellyA, JewellSD, et al.Biospecimen reporting for improved study quality. Biopreserv Biobank, 2011; 9:57–70.
38.
AlsayedH, OwaidahT, Al RawasF. Validation of a modified cryopreservation method for leukemic blasts for flow cytometry assessment. Hematol Oncol Stem Cell Ther, 2008; 1:94–97.
39.
EllervikC, VaughtJ. Preanalytical variables affecting the integrity of human biospecimens in biobanking. Clin Chem, 2015; 61:914–934.
40.
HubelA, SpindlerR, SkubitzAP. Storage of human biospecimens: Selection of the optimal storage temperature. Biopreserv Biobank, 2014; 12:165–175.
41.
SewartS, BarracloughR, RudlandPS, WestCR, BarracloughDL. Molecular analysis of a collection of clinical specimens stored at 4 degrees C as an alternative to snap-freezing. Int J Oncol, 2009; 35:381–386.
42.
KofanovaOA, DavisK, GlazerB, et al.Viable mononuclear cell stability study for implementation in a proficiency testing program: Impact of shipment conditions. Biopreserv Biobank, 2014; 12:206–216.
43.
OlsonWC, SmolkinME, FarrisEM, et al.Shipping blood to a central laboratory in multicenter clinical trials: Effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med, 2011; 9:26.
44.
GreytakSR, EngelKB, BassBP, MooreHM. Accuracy of molecular data generated with FFPE biospecimens: Lessons from the literature. Cancer Res, 2015; 75:1541–1547.
45.
BassBP, EngelKB, GreytakSR, MooreHM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: How well do you know your FFPE specimen?. Arch Pathol Lab Med, 2014; 138:1520–1530.
46.
LowenthalRM, ParkDS, GoldmanJM, HillRS, WhyteG, Th'ngKH. The cryopreservation of leukaemia cells: Morphological and functional changes. Br J Haematol, 1976; 34:105–117.
47.
LanzaF, MorettiS, CastagnariB, et al.Assessment of distribution of CD34 epitope classes in fresh and cryopreserved peripheral blood progenitor cells and acute myeloid leukemic blasts. Haematologica, 1999; 84:969–977.
48.
CamposL, GuyotatD, LareseA, et al.Expression of immunological markers on leukemic cells before and after cryopreservation and thawing. Cryobiology, 1988; 25:18–22.
49.
RadichJP, MaoM, StepaniantsS, et al.Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics, 2004; 83:980–988.
50.
DvingeH, RiesRE, IlaganJO, StirewaltDL, MeshinchiS, BradleyRK. Sample processing obscures cancer-specific alterations in leukemic transcriptomes. Proc Natl Acad Sci U S A, 2014; 111:16802–16807.
51.
AndersonJE, KopeckyKJ, WillmanCL, et al.Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study. Blood, 2002; 100:3869–3876.
52.
PetersdorfSH, RankinC, HeadDR, et al.Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (SWOG-9500). Am J Hematol, 2007; 82:1056–1062.
53.
GodwinJE, KopeckyKJ, HeadDR, et al.A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest oncology group study (9031). Blood, 1998; 91:3607–3615.
54.
ListAF, KopeckyKJ, WillmanCL, et al.Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood, 2001; 98:3212–3220.
55.
StirewaltDL, KopeckyKJ, MeshinchiS, et al.Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood, 2006; 107:3724–3726.
56.
OstronoffF, OthusM, HoPA, et al.Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: A SWOG report. Leukemia, 2013; 27:238–241.
57.
LeithCP, ChenIM, KopeckyKJ, et al.Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood, 1995; 86:2329–2342.
58.
MeshinchiS, AlonzoTA, StirewaltDL, et al.Clinical implications of FLT3 mutations in pediatric AML. Blood, 2006; 108:3654–3661.
59.
ThiedeC, SteudelC, MohrB, et al.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 2002; 99:4326–4335.
60.
StirewaltDL, MeshinchiS, KopeckyKJ, et al.Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer, 2008; 47:8–20.
61.
Pogosova-AgadjanyanEL, KopeckyKJ, OstronoffF, et al.The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. PLoS One, 2013; 8:e70812.
62.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001; 25:402–408.
63.
BruserudO, ReikvamH, FredlyH, et al.Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget, 2015; 6:2794–2811.
64.
VerschoorCP, KohliV, BalionC. A comprehensive assessment of immunophenotyping performed in cryopreserved peripheral whole blood. Cytometry B Clin Cytom, 2017. [Epub ahead of print]; http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21526/epdf (accessed November7, 2017).
65.
MohamedaliAM, AlkhatabiH, KulasekararajA, et al.Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood, 2013; 122:567–570.
66.
QuX, OthusM, DavisonJ, et al.Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. Cancer, 2017; 123:2472–2481.
67.
DohnerH, EsteyE, GrimwadeD, et al.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017; 129:424–447.
68.
HoPA, AlonzoTA, GerbingRB, et al.High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: A report from the children's oncology group. Br J Haematol, 2013; 162:670–677.
69.
KuhnlA, ValkPJ, SandersMA, et al.Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood, 2015; 125:2985–2994.
70.
Gallego RomeroI, PaiAA, TungJ, GiladY. RNA-seq: Impact of RNA degradation on transcript quantification. BMC Biol, 2014; 12:42.
71.
AaseboE, MjaavattenO, VaudelM, et al.Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. J Proteomics, 2016; 145:214–225.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
